Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility ...
NDTV Profit on MSN
Sahajanand Medical Technologies IPO GMP today: Grey market premium signals 13% listing gain
Sahajanand Medical Technologies IPO is expected to list at Rs 387 against the upper price band of Rs 344. The issue is worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results